The Weeknd’s After Hours Til Dawn tour tops $1.3 billion, Live Nation says

The Weeknd’s After Hours Til Dawn tour has topped $1.3 billion in ticket sales, according to Live Nation’s November 5th, 2026, announcement. The promoter calls it the highest-grossing tour by a male artist, putting a four-year stadium run at a new commercial milestone.
Live Nation reports more than 9 million tickets across 176 shows in 67 cities, 30 countries and five continents. The figures cover the full tour, which began in July 2022, rather than a single year or one regional leg.
The final year accounted for a substantial part of that total. According to the promoter, the tour sold more than 3 million tickets and grossed over $500 million during 2026. Live Nation says the run concluded in Kuala Lumpur after an Asian leg that expanded from 11 announced dates to 17 performances.
Pollstar’s report on the milestone likewise attributes the overall ticket and revenue figures to Live Nation. The touring publication places The Weeknd alongside Taylor Swift and Coldplay in the small group of acts whose tours have crossed the billion-dollar threshold. It also notes that he won its Best R&B Tour award earlier this year.
The distinction matters when reading a headline this large: gross ticket revenue measures sales before the costs of staging and operating a tour. It is not a statement of the performer’s take-home earnings. The reported attendance and geographic reach help explain the scale behind the financial total.
Live Nation also reports $8.5 million donated to the XO Humanitarian Fund and Global Citizen, including $3 million raised during 2026 for the World Food Programme and Global Citizen. Those charitable figures are reported separately from ticket revenue.
For R&B audiences, the result is another sign of how far a stadium production can travel when it sustains demand across multiple markets and years. PowerPage’s recent coverage of Usher and Chris Brown’s touring figures offers another view of the genre’s live-business reach.






Comments